CATALOGO DEI PRODOTTI DELLA RICERCA

SIMBOLO, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.242
EU - Europa 5.441
AS - Asia 3.801
SA - Sud America 509
Continente sconosciuto - Info sul continente non disponibili 240
AF - Africa 134
OC - Oceania 16
Totale 16.383
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.962
RU - Federazione Russa 2.163
SG - Singapore 1.304
CN - Cina 1.268
GB - Regno Unito 883
IT - Italia 856
BR - Brasile 387
HK - Hong Kong 356
DE - Germania 340
VN - Vietnam 311
SE - Svezia 283
IE - Irlanda 240
FR - Francia 223
FI - Finlandia 138
CA - Canada 132
KR - Corea 123
BD - Bangladesh 86
NL - Olanda 67
IN - India 62
JP - Giappone 52
UA - Ucraina 46
MX - Messico 39
AR - Argentina 38
ID - Indonesia 37
ES - Italia 36
TR - Turchia 35
PL - Polonia 31
AT - Austria 30
BE - Belgio 30
IQ - Iraq 29
NG - Nigeria 29
EC - Ecuador 23
CR - Costa Rica 22
BJ - Benin 18
CO - Colombia 18
PK - Pakistan 17
SA - Arabia Saudita 16
TG - Togo 16
ZA - Sudafrica 16
AU - Australia 14
MA - Marocco 14
VE - Venezuela 14
HN - Honduras 12
SV - El Salvador 12
UZ - Uzbekistan 12
PH - Filippine 11
CL - Cile 10
IR - Iran 10
NP - Nepal 10
PR - Porto Rico 10
IL - Israele 9
NI - Nicaragua 9
JM - Giamaica 8
JO - Giordania 8
LT - Lituania 8
TT - Trinidad e Tobago 8
LV - Lettonia 7
MY - Malesia 7
TN - Tunisia 7
UY - Uruguay 7
CH - Svizzera 6
EG - Egitto 6
GP - Guadalupe 6
GT - Guatemala 6
KG - Kirghizistan 6
AL - Albania 5
BB - Barbados 5
CZ - Repubblica Ceca 5
PE - Perù 5
SK - Slovacchia (Repubblica Slovacca) 5
TW - Taiwan 5
CW - ???statistics.table.value.countryCode.CW??? 4
EE - Estonia 4
ET - Etiopia 4
KE - Kenya 4
MT - Malta 4
PA - Panama 4
PT - Portogallo 4
PY - Paraguay 4
RS - Serbia 4
SC - Seychelles 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BG - Bulgaria 3
GA - Gabon 3
GR - Grecia 3
HR - Croazia 3
PS - Palestinian Territory 3
BO - Bolivia 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EU - Europa 2
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
Totale 16.114
Salva come PNG Salva come JPEG
Città #
Ashburn 828
Moscow 742
Southend 698
Singapore 683
San Jose 626
Dallas 516
Chandler 507
Hong Kong 345
Verona 338
Beijing 265
Dublin 235
Council Bluffs 212
New York 186
Ann Arbor 146
Woodbridge 145
Jacksonville 137
The Dalles 131
Los Angeles 125
Munich 122
Ho Chi Minh City 99
Santa Clara 88
Jinan 86
Redmond 78
Princeton 73
Lawrence 72
Milan 70
Wilmington 68
Hanoi 67
Shenyang 63
Helsinki 55
Houston 55
Nanjing 53
São Paulo 52
London 51
Columbus 46
Orem 46
Redondo Beach 46
Tianjin 46
Buffalo 45
Tokyo 44
Zhengzhou 41
Montreal 37
Bologna 36
Frankfurt am Main 36
Hebei 33
Turku 33
Brooklyn 29
Brussels 29
Haikou 29
Abuja 28
Ningbo 28
Phoenix 28
Sindelfingen 28
Warsaw 28
Changsha 27
Hangzhou 27
Nanchang 26
Seoul 26
Guangzhou 25
Chicago 24
Denver 24
Nuremberg 24
Seattle 24
Atlanta 22
Mexico City 22
Rome 22
Amsterdam 21
Poplar 21
Taizhou 21
Toronto 21
Vienna 21
Dearborn 20
San Francisco 20
Jakarta 19
Kent 19
Boston 18
Cotonou 18
Naples 18
Taiyuan 18
San José 17
Shanghai 17
Falls Church 16
Jiaxing 16
Lomé 16
Haiphong 15
Las Vegas 15
Rio de Janeiro 15
Dong Ket 14
Redwood City 14
Stockholm 14
Chennai 13
Da Nang 13
Falkenstein 13
Norwalk 13
Washington 13
Baghdad 12
Belo Horizonte 12
Johannesburg 12
Paris 12
St Louis 12
Totale 9.575
Salva come PNG Salva come JPEG
Nome #
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 319
Whole-genome landscape of pancreatic neuroendocrine tumours 297
DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples 294
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 266
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 265
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 251
Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing 250
A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics 236
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 236
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 236
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 224
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 223
High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. 221
Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers 221
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 219
IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation 218
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 214
Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients 213
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 212
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma 204
Reporting tumor molecular heterogeneity in histopathological diagnosis 204
Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers 203
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 196
Comparative Lesions Analysis Through a Targeted Sequencing Approach 196
H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology 194
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 192
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas 189
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 189
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 184
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 181
Next-generation sequencing for genetic testing of familial colorectal cancer syndromes 180
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis 179
MULTIGENE MUTATIONAL PROFILING OF CHOLANGIOCARCINOMAS IDENTIFIES ACTIONABLE MOLECULAR SUBGROUPS 178
ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance 178
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 178
FrequentNRG1fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression 177
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer 176
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 174
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 173
Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants 173
Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma 171
Exosomal miRNA signatures of pancreatic lesions 171
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations 169
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 167
Poorly Cohesive Gastric Cancers Showing the Transcriptomic Hallmarks of Epithelial-Mesenchymal Transition Behave Aggressively 167
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 166
Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization 166
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 164
Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumours display divergent genomic and transcriptomic profiles 159
Collapse of the Plasmacytoid Dendritic Cells compartment in advanced cutaneous melanomas by components of the tumor cell secretome 158
Long-term organoid culture of a small intestinal neuroendocrine tumor 156
Glioblastoma with tumor-to-tumor metastasis from lung adenocarcinoma 156
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 156
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 155
Techniques and New Diagnostic Technologies (Limitations, Applications) 155
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy 150
Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival 148
An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide 146
Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series 144
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report 143
An Insight on Functioning Pancreatic Neuroendocrine Neoplasms 141
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 141
Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology 140
Il profilo molecolare 139
pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells 136
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment 133
Atypical meningiomas with an immunohistochemical profile consistent with hypermetabolic or proliferative molecular groups show high mitotic index, chromosomal instability, and higher recurrence risk 132
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study 132
Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors 130
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives 127
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 127
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 126
Ascl1 and OTP tumor expressions are associated with Disease-Free Survival in Lung Atypical Carcinoids 125
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres) 125
Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients 124
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities 124
Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report 122
Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis 121
MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma 117
Pathology of Biliary Tract Cancers 117
Tubulocystic Carcinoma of Bile Ducts: A Distinct Type of Cholangiocarcinoma Associated With Adenofibroma-type Lesions 115
New genomic landscapes and therapeutic targets for biliary tract cancers 115
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 113
Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC) 112
Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance 112
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer 111
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 108
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 104
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 102
Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification? 100
Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 95
Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades 94
Metastasis of lung carcinoid in the thyroid gland after 18 years: it is never too late. A case report and review of the literature 90
Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms 89
Combined adenocarcinoma–atypical carcinoid of the lung. Targeted Next-Generation Sequencing (NGS) suggests a monoclonal origin of the two components 89
Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations 87
Hepatocellular Carcinoma Genetic Landscape 82
Exploring the molecular and biological background of lung neuroendocrine tumours 81
Lung carcinoid tumours: histology and Ki-67, the eternal rivalry 74
Oncocytic and spindle cell typical carcinoids of lung: different immunophenotype and biological behavior 58
Totale 16.190
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.367
article - articoli 53.782
book - libri 0
conference - conferenze 2.438
curatela - curatele 0
other - altro 1.492
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.655
Totale 118.734
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022406 0 0 0 0 44 18 36 51 37 17 58 145
2022/20231.484 88 172 112 256 127 351 16 84 198 17 34 29
2023/2024867 40 59 82 91 109 154 49 63 12 53 131 24
2024/20252.250 115 119 123 383 79 89 117 87 310 146 229 453
2025/20267.213 503 332 509 1.209 1.895 431 616 389 561 450 156 162
2026/20271.412 122 248 255 737 50 0 0 0 0 0 0 0
Totale 16.383